Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer
NCT01090128
Terminated
The purpose of this clinical trial is to test whether treatment of patients with breast cancer with the combination of Abraxane (nab-paclitaxel), Adriamycin (doxorubicin), and Cyclophosphamide prior to surgery is safe and results in good tumor response. Up to 24 patients may be enrolled in this study at the Mitchell Cancer Institute. All patients enrolling in this study will receive treatment with the combination of Abraxane, Adriamycin, and Cyclophosphamide.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/29/2017
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Stages II-III Breast Cancer
Register for Updates
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
NCT01222715
Completed
This randomized phase II trial studies how well vinorelbine tartrate and cyclophosphamide work in combination with bevacizumab or temsirolimus in treating patients with recurrent or refractory rhabdomyosarcoma. Drugs used in chemotherapy, such as vinorelbine tartrate and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Som... Read More
Gender:
ALL
Ages:
29 years and below
Trial Updated:
03/24/2017
Locations: Children's Hospital of Alabama, Birmingham, Alabama +183 locations
Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
Register for Updates
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
NCT00578266
Completed
For patients with severe aplastic anemia (SAA) who have failed to respond to immunosuppressive therapy and lack an HLA identical family member, our objectives are to make an initial assessment of the safety and efficacy of allogenic stem cell transplantation from either a matched unrelated donor or a mismatched reacted donor using the conditioning regimen of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle measures of safety and efficacy will be : 1. Patient survival... Read More
Gender:
ALL
Ages:
60 years and below
Trial Updated:
03/23/2017
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Anemia, Aplastic
Register for Updates
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
NCT00104299
Completed
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ab... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
03/23/2017
Locations: University of Alabama, Birmingham, Alabama +7 locations
Conditions: Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
Register for Updates
Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
NCT00343785
Completed
This clinical trial is studying how well giving cyclophosphamide together with anti-thymocyte globulin followed by methotrexate and cyclosporine works in preventing chronic graft-vs-host disease (GVHD) in patients with severe aplastic anemia undergoing donor bone marrow transplant. Giving low doses of chemotherapy, such as cyclophosphamide, before a donor bone marrow transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's stem cell... Read More
Gender:
ALL
Ages:
65 years and below
Trial Updated:
03/16/2017
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah +2 locations
Conditions: Aplastic Anemia
Register for Updates
Phase II ABT-888 With Cyclophosphamide
NCT01306032
Completed
Background: - The experimental cancer treatment drug ABT-888 (Veliparib) works by preventing deoxyribonucleic acid (DNA) repair in tumor cells. Cyclophosphamide is a cancer treatment drug that works by causing DNA damage in cells, including cancer cells, resulting in cell death. However, because cyclophosphamide has strong and unpleasant side effects, researchers are interested in finding drugs that can be given in combination with cyclophosphamide that will allow a lower dose of cyclophosphami... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2017
Locations: University of California, Davis, Davis, California +9 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Register for Updates
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259
Completed
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more ef... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/15/2017
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +174 locations
Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
NCT01943188
Terminated
This pilot phase I trial studies the side effects and best way to give stereotactic body radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer. Giving total body irradiation before a T-cell infusion stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. Chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then ret... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2017
Locations: Stanford University Hospitals and Clinics, Stanford, California
Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Register for Updates
Surgery in Treating Children With Neuroblastoma
NCT00003119
Completed
RATIONALE: Surgery alone may be effective in treating children with neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of surgery alone in treating children who have neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/09/2017
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +234 locations
Conditions: Neuroblastoma
Register for Updates
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
NCT00941330
Completed
The patients are being asked to take part in this study because they have a hormone receptor-positive breast cancer (contains estrogen and/or progesterone receptors) and their doctor has told them that they have an option to receive chemotherapy or hormonal therapy before surgery. The purpose of this study is to assess if chemotherapy using docetaxel and cytoxan (TC) or hormonal therapy using exemestane can shrink the size of their breast tumor and allow them to preserve the breast or have less... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2017
Locations: Grady Memorial Hospital, Atlanta, Georgia +2 locations
Conditions: Breast Cancer
Register for Updates
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
NCT01004991
Completed
This is a phase I/II open label, multi-center study of azacytidine in combination with standard RCHOP therapy in patients with DLBCL. Patients will be treated with azacytidine at escalating doses on days 1-5, followed by standard dose rituximab plus CHOP chemotherapy on day 8, every 21 days. Patients will be treated for a total 6 cycles. The phase II portion will then evaluate efficacy of the combination at the established MTD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2017
Locations: Weill Cornell Medical College, New York, New York
Conditions: Diffuse Large B Cell Lymphoma
Register for Updates
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
NCT00683670
Completed
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2017
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Melanoma
Register for Updates